ASBMR Symposium: The Effects of Diabetes and Disordered Energy Metabolism on Skel
ASBMR Symposium: The Effects of Diabetes and Disordered Energy Metabolism on Skel
批准号:
8785584
负责人:
ANN V SCHWARTZ
金额:
$3.8万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-13 至 2015-07-31
关键词:
2,4-thiazolidinedioneAccountingAddressAdvanced Glycosylation End ProductsAffectAgeAntidiabetic DrugsAreaAwarenessBasic ScienceBiochemical MarkersBiologyBlood VesselsClinicalClinical ManagementClinical MedicineClinical ResearchCollaborationsCollagenCommunicationDataDevelopmentDiabetes MellitusDiagnosisDiseaseElderlyEnergy MetabolismEpidemiologyExcess MortalityFractureGastrointestinal HormonesGlucagonGlucoseGoalsHealthHip FracturesHomeostasisHormonesHospitalizationHumanInsulinInsulin ResistanceInsulin-Dependent Diabetes MellitusInterdisciplinary StudyInvestigationLifeLife ExpectancyMindMorbidity - disease rateNon-Insulin-Dependent Diabetes MellitusOsteocalcinOsteoporosisPPAR gammaPatientsPeptidesPharmaceutical PreparationsPopulationPre-Clinical ModelPrediabetes syndromeProcessPropertyProteinsPublic HealthResearchResearch PersonnelRiskRisk AssessmentRisk EstimateRisk FactorsSkeletonThiazolidinedionesTreatment CostWalkingage groupbasebonebone cellbone metabolismbone qualitycostdiabeticdiabetic patientexperiencehigh riskimprovedmeetingsposterspublic health relevanceskeletalsymposiumtooltranslational medicine
中文摘要
描述(由申请人提供):在美国,每年有200万老年人经历骨折,治疗费用为170亿美元。1型糖尿病患者的血糖水平明显高于2型糖尿病患者。因此,骨折的发病率,已经被确定为一个重要的公共卫生问题,在更广泛的老年人群体中,在糖尿病患者中甚至更普遍。糖尿病骨的质量受到损害,但其原因尚不清楚,这阻碍了糖尿病患者诊断和治疗骨质疏松症的能力。目前的临床工具低估了糖尿病患者的骨折风险,并且改善风险评估的目标已经刺激了对糖尿病骨的生化标志物、微观结构和材料特性的研究。越来越多的人意识到糖尿病药物可能会对骨骼产生影响。这是研究能量代谢紊乱对骨骼影响的关键时刻和机会。在临床和基础生物学领域正在取得进展。然而,由于缺乏跨骨和能量代谢研究的交流场所,以及基础科学、流行病学、转化医学和临床医学研究人员之间的分离,进展受到阻碍。这次专题讨论会将提供一个在会议期间进行互动的场所,并通过散发会后摘要,使与会者以外的人也能参与,使这项研究达到一个新的成熟水平。具体目标是:1)介绍关于能量代谢紊乱和糖尿病对骨生物学影响的最新研究,包括对骨细胞、材料特性和微观结构的影响; 2)介绍关于糖尿病患者骨质疏松症诊断和管理以及糖尿病治疗对骨骼的潜在影响的最新研究; 3)促进基础、骨质疏松症和糖尿病研究的转化和临床研究人员。专题讨论会将在海报会议、午餐期间以及通过青年和高级调查员的聚餐提供互动和合作的机会。通过邀请国际知名的研究人员介绍他们在了解胰岛素抵抗方面的最新进展,糖尿病和骨的临床前模型的经验教训,糖尿病患者的人体骨代谢,糖尿病药物对骨的影响,FRAX在糖尿病患者中的局限性和糖尿病相关的骨折风险因素,以及糖尿病患者的药物治疗方面的最新数据,
糖尿病患者的骨质疏松症。研讨会将以一个临床专家小组结束,该小组将讨论“临床管理:已知的和需要更多研究的地方?“将鼓励与会者参加研讨会后的ASBMR 2014年年会,反之亦然。将提供支助,鼓励年轻调查员参加。研讨会将产生更好地了解糖尿病和骨骼,弥合基础科学,转化和临床领域的研究人员之间的差距,增加骨骼和能量代谢研究人员之间的沟通和互动,并为这一关键研究领域提供显着的成熟。
英文摘要
DESCRIPTION (provided by applicant): In the U.S., 2 million older adults experience a fracture annually with treatment costs of $17 billion. Those with type 1 or type 2 diabetes have an increased fracture risk. Thus, the morbidity from fractures, already identified as an important public health issue in the broader population of older adults, is even more prevalent among those with diabetes. The quality of diabetic bone is compromised but the reasons for this are not understood, impeding the ability to diagnose and treat osteoporosis in diabetic patients. Current clinical tools under- estimate fracture risk in diabetic patients, and the goal of improving risk assessment has spurred investigations into biochemical markers, microstructure and material properties of diabetic bone. There is increasing awareness that diabetes medications may have skeletal effects. This is a crucial juncture and opportunity for research into the effects of disordered energy metabolism on bone. Advances are being made in the clinical and basic biology arenas. However, progress is hampered by the lack of venues for communication across bone and energy metabolism research and by separations among investigators in basic science, epidemiology, and translational and clinical medicine. This symposium will provide a venue for interaction at the meeting itself and through dissemination of post-meeting summaries, reaching well beyond those in attendance and bringing a new level of maturity to this research. The specific aims are 1) To present the latest research on the effects of disordered energy metabolism and diabetes on bone biology, including effects on bone cells, material properties and microstructure, 2) To present the latest research on the diagnosis and management of osteoporosis in patients with diabetes and on the potential skeletal effects of diabetes treatments and 3) To promote interaction among basic, translational and clinical researchers in osteoporosis and diabetes research. The symposium will provide opportunities for interactions and collaborations at the poster sessions, during lunch and through a dine-around for young and senior investigators. The aims will be accomplished by inviting internationally known researchers to present their latest data on advances in understanding insulin resistance, lessons from preclinical models of diabetes and bone, human bone metabolism in diabetes, the effects of diabetic medications on bone, the limitations of FRAX in diabetic patients and diabetes-related risk factors for fracture, and pharmacological therapies for
osteoporosis in diabetic patients. The symposium will conclude with a panel of clinical experts addressing "Clinical management: what is known and where is more research needed?" Attendees will be encouraged to attend the ASBMR 2014 Annual Meeting following the symposium and vice versa. Support will be provided to encourage young investigators to attend. The symposium will generate a better understanding of diabetes and bone, bridge the gaps among investigators in the basic science, translational and clinical arenas, increase communication and interaction among investigators in bone and in energy metabolism, and provide significant maturation for this crucial area of research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Skeletal Health in Type 1 Diabetes and the Role of Diabetic Kidney Disease
-
批准号:10684140
-
项目类别:
-
资助金额:$66.92万
-
财政年份:2020
-
负责人:ANN V SCHWARTZ
-
依托单位:
Skeletal Health in Type 1 Diabetes and the Role of Diabetic Kidney Disease
-
批准号:10032520
-
项目类别:
-
资助金额:$78.01万
-
财政年份:2020
-
负责人:ANN V SCHWARTZ
-
依托单位:
Skeletal Health in Type 1 Diabetes and the Role of Diabetic Kidney Disease
-
批准号:10459481
-
项目类别:
-
资助金额:$66.62万
-
财政年份:2020
-
负责人:ANN V SCHWARTZ
-
依托单位:
Skeletal Health in Type 1 Diabetes and the Role of Diabetic Kidney Disease
-
批准号:10256021
-
项目类别:
-
资助金额:$69.16万
-
财政年份:2020
-
负责人:ANN V SCHWARTZ
-
依托单位:
Undercarboxylated osteocalcin, body fat, and diabetes in older adults
-
批准号:7738539
-
项目类别:
-
资助金额:$22.01万
-
财政年份:2009
-
负责人:ANN V SCHWARTZ
-
依托单位:
Undercarboxylated osteocalcin, body fat, and diabetes in older adults
-
批准号:7896451
-
项目类别:
-
资助金额:$12.59万
-
财政年份:2009
-
负责人:ANN V SCHWARTZ
-
依托单位:
Intensive Glycemic Control and Skeletal Health
-
批准号:7121944
-
项目类别:
-
资助金额:$48.03万
-
财政年份:2005
-
负责人:ANN V SCHWARTZ
-
依托单位:
Intensive Glycemic Control and Skeletal Health
-
批准号:7660507
-
项目类别:
-
资助金额:$43.8万
-
财政年份:2005
-
负责人:ANN V SCHWARTZ
-
依托单位:
Intensive Glycemic Control and Skeletal Health
-
批准号:6965816
-
项目类别:
-
资助金额:$51.18万
-
财政年份:2005
-
负责人:ANN V SCHWARTZ
-
依托单位:
Intensive Glycemic Control and Skeletal Health
-
批准号:7477402
-
项目类别:
-
资助金额:$5.18万
-
财政年份:2005
-
负责人:ANN V SCHWARTZ
-
依托单位:
Intensive Glycemic Control and Skeletal Health
-
批准号:7278810
-
项目类别:
-
资助金额:$42.79万
-
财政年份:2005
-
负责人:ANN V SCHWARTZ
-
依托单位:
Intensive Glycemic Control and Skeletal Health
-
批准号:7489286
-
项目类别:
-
资助金额:$45.92万
-
财政年份:2005
-
负责人:ANN V SCHWARTZ
-
依托单位:
DIABETES, PRE-DIABETES, AND FALLS IN OLDER ADULTS
-
批准号:6759234
-
项目类别:
-
资助金额:$12.38万
-
财政年份:2003
-
负责人:ANN V SCHWARTZ
-
依托单位:
DIABETES, PRE-DIABETES, AND FALLS IN OLDER ADULTS
-
批准号:6668114
-
项目类别:
-
资助金额:$12.38万
-
财政年份:2003
-
负责人:ANN V SCHWARTZ
-
依托单位:
海外基金